Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Raymond James

Spotify Shares Jump On Analyst Upgrade, Drawing Parallels With Netflix

Raymond James analyst Andrew Marok upgraded Spotify Technology S.A. (NYSE:SPOT) to Outperform from Market Perform with a $150 price target. The stock has traded off significantly from all-time highs in early 2021 due to slower than expected scaling of the company's podcasting business and, most recently, soft margin guidance. Marok saw the bad news as…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Upgrades

Benzinga

9 Salesforce Analysts React To Q1 Earnings Beat: 'Next Quality Software GARP Stock'

Salesforce Inc (NYSE: CRM) shares jumped Wednesday morning after the company reported first-quarter earnings and raised its profit forecast.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CD&R, TPG Take Covetrus Private In $4B Deal

Clayton, Dubilier & Rice (CD&R), a private investment firm, and TPG Capital will acquire animal-health technology and services company Covetrus Inc (NASDAQ:CVET) for $21.00 per share, representing an enterprise value of approximately $4 billion. CD&R and its affiliates currently beneficially own approximately 24% of the company's outstanding shares of common stock. The transaction…

Benzinga

A Warning Sign For Other Advertisers? Snapchat Analysts React To Shocking Guidance Cut, Stock Sell-Off

Snap Inc (NYSE: SNAP) shares are plummeting 40% after CEO Evan Spiegel warned employees the company will miss its targets for revenue and earnings in the second quarter.

Benzinga

Raymond James View Skewed Scenarios On Absent Supportive Bid For This Animal Health Stock

Raymond James downgraded the rating on Covetrus Inc (NASDAQ:CVET) from Outperform to Market Perform and removed the prior $22 price target after the company received a buyout at $21 per share. Though $21 may not ultimately prove to be the final resting place in terms of the offer price. Raymond James believes the proposed purchase…

Benzinga

Raymond James Is Bullish On CubeSmart, Public Storage - Read Why

Raymond James analyst Jonathan Hughes upgraded CubeSmart (NYSE:CUBE) from Outperform to Strong Buy and lowered the price target from $60 to $52 (24.6% upside). Hughes maintained Public Storage (NYSE:PSA) with a Strong Buy and lowered the price target from $375 to $365 (15.7% upside). The self-storage REITs were vulnerable to the recent sell-off despite the positive fundamental updates. They…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

Benzinga

5 Walmart Analysts React To Mixed Q1 Earnings: 'Particularly Attractive Buying Opportunity'

Walmart Inc (NYSE: WMT) shares were in the clearance aisle Wednesday after the company reported rising costs related to supply chain problems and inflation in the first quarter.

Benzinga

Check Out What Whales Are Doing With CVX

Someone with a lot of money to spend has taken a bullish stance on Chevron (NYSE:CVX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read Why Did Raymond James Slash Price Target On Inflarx

Raymond James remains a Strong Buy on Inflarx NV (NASDAQ: IFRX) following 1Q22 earnings based on a promising outlook for vilobelimab in Pyoderma Gangrenosum (PG) and potentially other indications. The biotech macro backdrop has forced many companies to be prudent with cash runway and prioritize clinical programs. InflaRx is also focusing on a potential pivotal trial…

Benzinga

Check Out What Whales Are Doing With CVX

Benzinga

Raymond James Maintains Outperform Rating for MeridianLink: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of MeridianLink (NYSE:MLNK) and lower its price target from $27.00 to $21.00. Shares of MeridianLink are trading up 12.15% over the last 24 hours, at $16.25 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Raymond James Sees 'Pipeline Key Success Factor' For This MedTech Stock

Raymond James has reiterated Outperform rating on LumiraDx Limited's (NASDAQ:LMDX) shares after 1Q revenue beat but lower than expected margins that ultimately do very little to impact long-term views of the company. They lowered the price target from $9 to $7. Revenues were 7% above Raymond James' view and 12% above consensus. The beat was…

Benzinga

Bumble Shares Soar On Analyst Confidence Post Q1 Beat

Analysts expressed optimism on Bumble Inc (NASDAQ: BMBL) post Q1 beat. Raymond James analyst Andrew Mar

Benzinga

Raymond James Says 'Supply Chain Challenges Made Q1 Messy' For This Medtech Stock

ICU Medical Inc (NASDAQ:ICUI) reported Q1 sales of $543.1 million vs. Raymond James' estimate of $530 million. Core ICU beat by $7 million, while newly acquired Smiths Medical missed by $5 million. With an Outperform rating, the analysts lowered the price target from $265 to $235. Adjusted EPS was $1.82, down from Raymond James' estimate…

Benzinga

Check Out What Whales Are Doing With DVN

A whale with a lot of money to spend has taken a noticeably bullish stance on Devon Energy. Looking at options history for Devon Energy (NYSE:DVN) we detected 15 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

Upgrades

Benzinga

10 Biggest Price Target Changes For Wednesday

Raymond James cut Electronic Arts Inc. (NASDAQ: EA) price target from $158 to $150. Electronic Arts shares rose 3.8% to $115.84 in pre-market trading.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022

Upgrades

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

Benzinga

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

Benzinga

Raymond James Maintains Strong Buy Rating for Cushman & Wakefield: Here's What You Need To Know

Raymond James has decided to maintain its Strong Buy rating of Cushman & Wakefield (NYSE:CWK) and raise its price target from $32.00 to $35.00. Shares of Cushman & Wakefield are trading up 4.48% over the last 24 hours, at $19.00 per share.

Benzinga

Johnson & Johnson Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 10 strange trades.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.